Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aranesp Medicare reimbursement increase

Executive Summary

Medicare Part B reimbursement for Amgen's Aranesp will increase 37% from $2.37 to $3.24 per microgram under 2004 hospital prospective payment system 1final rule published Oct. 31. Amgen and Procrit maker J&J have been trading data submissions to Centers for Medicare & Medicaid Services since agency established "functional equivalence" standard for reimbursement of the anemia products (2"The Pink Sheet" Aug. 11, 2003, p. 23). Decision is step in the right direction, Amgen says...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel